ArticleScience translational medicine2018
A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Circulating biomarkers during progression to type 1 diabetes: A systematic review.Frontiers in endocrinology · 2023Pooled it
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Lentinan alleviates metabolic dysfunction implicatingFrontiers in nutrition · 2026Article
- Inhibition of pyrimidine de novo synthesis fosters Treg cells and reduces diabetes development in models of Type 1 Diabetes.Molecular metabolism · 2025Article
- NFAT5: a stress-related transcription factor with multiple functions in health and disease.Cell stress · 2025Review
- Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.Frontiers in immunology · 2025Article
- Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy.Biomarker research · 2024Review
- Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024Review
- MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis.Experimental and therapeutic medicine · 2024Article
- Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration.Cell metabolism · 2023Article
- Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.Molecular therapy oncolytics · 2023Review
- Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes: miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion.Non-coding RNA · 2023Article
- Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review.Biomedicines · 2022Review
- MYC-mediated silencing of miR-181a-5p promotes pathogenic Th17 responses by modulating AKT3-FOXO3 signaling.iScience · 2022Article
- Circular RNA has Circ 001372-Reduced Inflammation in Ovalbumin-Induced Asthma Through Sirt1/NFAT5 Signaling Pathway by miRNA-128-3p.Molecular biotechnology · 2022Article
- Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes.International journal of molecular sciences · 2022Review
- Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.Pharmaceutics · 2022Review
- Modeling human T1D-associated autoimmune processes.Molecular metabolism · 2022Review
- Progression of Type 1 Diabetes: Circulating MicroRNA Expression Profiles Changes from Preclinical to Overt Disease.Journal of immunology research · 2022Article
- T cell transgressions: Tales of T cell form and function in diverse disease states.International reviews of immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 12 institutions in 3 countries.
Isabelle SerrGroup Immune Tolerance in Type 1 Diabetes, Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany.ORCID 0000-0001-9277-9055
Martin G SchermGroup Immune Tolerance in Type 1 Diabetes, Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany.
Adam M ZahmDepartment of Genetics and Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jonathan SchugDepartment of Genetics and Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Victoria K FlynnGroup Immune Tolerance in Type 1 Diabetes, Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany.
Markus HippichDeutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Germany.ORCID 0000-0001-6253-2596
Stefanie KälinDeutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Germany.
Maike BeckerGroup Immune Tolerance in Type 1 Diabetes, Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany.ORCID 0000-0001-6416-4213
Peter AchenbachDeutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Germany.
Alexei NikolaevInstitute for Molecular Medicine, Universitätsmedizin der Johannes-Gutenberg-Universität, Mainz, Germany.
Katharina GerlachDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Erlangen, Germany.
Nicole LiebschDepartment of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Hemholtz Centre for Infection Research (HZI), Saarbrücken, Germany.ORCID 0000-0002-2154-554X
Brigitta LoretzDepartment of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Hemholtz Centre for Infection Research (HZI), Saarbrücken, Germany.ORCID 0000-0003-0057-5181
Claus-Michael LehrDepartment of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Hemholtz Centre for Infection Research (HZI), Saarbrücken, Germany.ORCID 0000-0002-5864-8462
Benedikt KirchnerPhysiology Weihenstephan, Technische Universität München, Munich, Germany.
Melanie SpornraftPhysiology Weihenstephan, Technische Universität München, Munich, Germany.
Bettina HaaseGenomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID 0000-0001-8945-7282
James SegarsJohn Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-5969-376X
Christoph KüperDepartment of Physiology, University of Munich, Munich, Germany.
Ralf PalmisanoOptical Imaging Centre Erlangen, University Erlangen, 91052 Erlangen, Germany.ORCID 0000-0003-4283-2115
Ari WaismanInstitute for Molecular Medicine, Universitätsmedizin der Johannes-Gutenberg-Universität, Mainz, Germany.ORCID 0000-0003-4304-8234
Richard A WillisEmory Vaccine Center, NIH Tetramer Core Facility, Atlanta, GA 30329, USA.
Wan-Uk KimPostech-Catholic Biomedical Engineering Institute, Catholic University of Korea, Seoul, Republic of Korea.
Benno WeigmannDepartment of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Erlangen, Germany.
Klaus H KaestnerDepartment of Genetics and Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Anette-Gabriele ZieglerDeutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Germany.
Carolin DanielGroup Immune Tolerance in Type 1 Diabetes, Institute for Diabetes Research, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany. carolin.daniel@helmholtz-muenchen.de.ORCID 0000-0003-4698-7069
German Center for Diabetes Research · DEHelmholtz Zentrum München · DEHelmholtz Institute for Pharmaceutical Research Saarland · DEUniversity of Pennsylvania · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEJohannes Gutenberg University Mainz · DETechnical University of Munich · DECatholic University of Korea · KREuropean Molecular Biology Laboratory · DEJohns Hopkins University · USTetra Tech (United States) · USUniversitätsklinikum Erlangen · DE
Funding
Penn integrated Human Pancreas procurement and Analysis ProgramUC4DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R, FELDMAN, MICHAEL D · 2016 to 2020
$17.8MRole of microRNAs in pediatric inflammatory bowel diseaseK01DK102868 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI ZAHM, ADAM MATTHEW · 2015 to 2019
$665kNIDDK NIH HHS K01 DK102868NIDDK NIH HHS UC4 DK112217
Abstract
Molecular checkpoints that trigger the onset of islet autoimmunity or progression to human type 1 diabetes (T1D) are incompletely understood. Using T cells from children at an early stage of islet autoimmunity without clinical T1D, we find that a microRNA181a (miRNA181a)-mediated increase in signal strength of stimulation and costimulation links nuclear factor of activated T cells 5 (NFAT5) with impaired tolerance induction and autoimmune activation. We show that enhancing miRNA181a activity increases NFAT5 expression while inhibiting FOXP3
Indexed as
AnimalsAntagomirsCD4-Positive T-LymphocytesDiabetes Mellitus, Type 1FemaleForkhead Transcription FactorsHumansImmunogeneticsMiceMice, Mutant StrainsMicroRNAsNFATC Transcription FactorsAntagomirsForkhead Transcription FactorsFoxp3 protein, mouseMicroRNAsNFATC Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.